Curi Bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$10M
- Investors
-
11
Curi Bio General Information
Description
Developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data. The company's technology provides a suite of products for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research, which promotes in vivo maturation and alignment of cell types, enabling drug developers to accurately test the safety and efficacy of new drugs.
Contact Information
Website
www.curibio.comCorporate Office
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Corporate Office
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Curi Bio Timeline
Curi Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series B) | 02-Dec-2025 | $10M | Completed | Generating Revenue | ||
| 11. Grant | 23-Aug-2023 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series A) | 29-Dec-2021 | Completed | Generating Revenue | |||
| 9. Grant | 01-Sep-2020 | Completed | Generating Revenue | |||
| 8. Debt - PPP | 06-Apr-2020 | Completed | Generating Revenue | |||
| 7. Grant | 01-Sep-2019 | Completed | Startup | |||
| 6. Grant | 20-May-2019 | Completed | Startup | |||
| 5. Seed Round | 16-May-2018 | Completed | Startup | |||
| 4. Grant | 01-Jan-2017 | $225K | Completed | Startup | ||
| 3. Grant | 01-Sep-2016 | $214K | Completed | Startup |
Curi Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B-1 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 6,794,993 | $0.100000 | 8% | $0.22 | $0.22 | 1x | $0.22 | 6.39% |
| Series A | 20,362,451 | $0.100000 | 8% | $0.49 | $0.49 | 1x | $0.49 | 19.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Curi Bio Comparisons
Industry
Financing
Details
Curi Bio Competitors (2)
One of Curi Bio’s 2 competitors is Owkin, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Owkin | Venture Capital-Backed | Paris, France | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA |
Curi Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Curi Bio Patents
Curi Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206911-A1 | Tissue imaging systems, instruments, and methods using fiducial. geometry-based displacement determination | Pending | 24-Mar-2025 | ||
| AU-2025263270-A1 | Optoreactive tissue stimulation systems | Pending | 22-Apr-2024 | ||
| WO-2025226629-A1 | Optoreactive tissue stimulation systems | Pending | 22-Apr-2024 | ||
| AU-2025257369-A1 | Optical measurement of labeled and label-free tissue contractility | Pending | 17-Apr-2024 | ||
| WO-2025221971-A1 | Optical measurement of labeled and label-free tissue contractility | Pending | 17-Apr-2024 | B01L9/523 |
Curi Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Curi Bio Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dream CIS | Corporation | Minority | ||
| National Center For Advancing Translational Sciences | Government | |||
| National Heart, Lung, and Blood Institute | Government | |||
| DS Asset Management | Asset Manager | Minority | ||
| Dynamk Capital | Venture Capital | Minority |
Curi Bio Investments & Acquisitions (4)
Curi Bio’s most recent deal was a Merger/Acquisition with CarTox. The deal was made on 29-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CarTox | 29-Mar-2022 | Merger/Acquisition | Decision/Risk Analysis | ||
| Celogics | 26-Oct-2021 | Joint Venture | Biotechnology | ||
| Dana Solutions | 23-Jul-2020 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| Silene Biotech | 25-Sep-2019 | Merger/Acquisition | Biotechnology |
Curi Bio FAQs
-
When was Curi Bio founded?
Curi Bio was founded in 2015.
-
Where is Curi Bio headquartered?
Curi Bio is headquartered in Seattle, WA.
-
What is the size of Curi Bio?
Curi Bio has 47 total employees.
-
What industry is Curi Bio in?
Curi Bio’s primary industry is Discovery Tools (Healthcare).
-
Is Curi Bio a private or public company?
Curi Bio is a Private company.
-
What is the current valuation of Curi Bio?
The current valuation of Curi Bio is .
-
What is Curi Bio’s current revenue?
The current revenue for Curi Bio is .
-
How much funding has Curi Bio raised over time?
Curi Bio has raised $20.1M.
-
Who are Curi Bio’s investors?
Dream CIS, National Center For Advancing Translational Sciences, National Heart, Lung, and Blood Institute, DS Asset Management, and Dynamk Capital are 5 of 11 investors who have invested in Curi Bio.
-
Who are Curi Bio’s competitors?
Owkin and Numerion Labs are competitors of Curi Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
